Related Experiment Video
Updated: Nov 5, 2025
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.7K
Differences between the quality aspects of various generic and branded docetaxel formulations
1Department of Breast Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China.
Current Medical Research and Opinion
|May 17, 2021
Summary
Generic docetaxel formulations often contain inadequate active drug and high impurities, leading to increased patient toxicities. Ensuring consistent quality and safety in all docetaxel formulations is crucial for cancer patients.
Area of Science:
- Oncology
- Pharmaceutical Sciences
- Drug Formulation
Background:
- Docetaxel is a critical chemotherapy agent with a narrow therapeutic window.
- Generic docetaxel formulations have raised concerns regarding increased patient toxicities.
- Polymeric micelles offer potential for targeted drug delivery to tumors, reducing systemic toxicity.
Purpose of the Study:
- To review pharmaceutical challenges in docetaxel formulations.
- To investigate quality and safety differences between branded and generic docetaxel.
- To highlight the impact of formulation variations on patient safety and adverse events.
Main Methods:
- Comprehensive literature review of studies comparing docetaxel formulations.
- Analysis of reported impurities, active drug quantities, and excipient variations.
- Examination of adverse event data linked to formulation changes.
Main Results:
- 90% of generic docetaxel formulations showed inadequate active drug content and high impurity levels.
- Elevated levels of solvents like polysorbate 80 and ethanol correlated with severe toxicities (febrile neutropenia, hematological, cutaneous).
- Minor formulation changes, including excipients and unbound drug fraction, were linked to adverse events.
Conclusions:
- Significant quality and safety disparities exist between branded and generic docetaxel formulations.
- Variations in generic docetaxel can lead to serious adverse events, impacting patient outcomes.
- There is an urgent need for global consistency assessment and stringent bioequivalence studies for all docetaxel formulations to ensure patient safety.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
47
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
47
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
39
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
39
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
46
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
46
01:16Bioequivalence: Overview
1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K
01:26Pharmaceutical Equivalents
48
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
48
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
47
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
47